- Home
- XERS vs PRA Comparison
XERS vs PRA Comparison
Compare XERS & PRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XERS | PRA |
|---|---|---|
| Founded | 2005 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.3B |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | XERS | PRA |
|---|---|---|
| Price | $6.19 | $24.47 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | $10.83 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 1.6M | 745.7K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | 0.01 | ★ 0.16 |
| Revenue | $49,590,000.00 | ★ $1,098,028,000.00 |
| Revenue This Year | $34.37 | N/A |
| Revenue Next Year | $22.86 | N/A |
| P/E Ratio | $623.50 | ★ $153.94 |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $4.30 | $22.79 |
| 52 Week High | $10.08 | $24.85 |
Technical Indicators
Market Signals| Indicator | XERS | PRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.90 | 39.59 |
| Support Level | $5.81 | $23.88 |
| Resistance Level | $6.41 | $24.79 |
| Average True Range (ATR) | 0.31 | 0.11 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 30.21 | 1.54 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About PRA ProAssurance Corporation
ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in four segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.